Working... Menu
Trial record 17 of 312 for:    IBRUTINIB

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02943473
Recruitment Status : Recruiting
First Posted : October 24, 2016
Last Update Posted : March 22, 2019
Pharmacyclics LLC.
Information provided by (Responsible Party):
Ajai Chari, Icahn School of Medicine at Mount Sinai

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2023
  Estimated Study Completion Date : December 2023